Bio-Techne Launches Early Access Program for Novel Spatial Protein Proximity Detection Technology
Bio-Techne Corporation (NASDAQ: TECH), a global leader in advanced life science tools, has announced an Early Access Program for a cutting-edge spatial biology assay that enables high-resolution detection of protein proximity within intact tissues. This next-generation tool, which builds on the proven RNAscope™ platform developed by Advanced Cell Diagnostics, is designed to illuminate functional protein interactions at a subcellular level — offering unprecedented insights into molecular signaling and its role in disease.
The newly developed assay moves beyond simply identifying the presence of proteins in tissues. By visualizing where proteins are interacting, it helps researchers better understand the functional context that drives biological processes and disease mechanisms.
“This new protein proximity assay opens the door to seeing functional interactions between proteins and not merely their presence in a tissue,” said Dr. Matt McManus, President of Bio-Techne’s Diagnostics & Spatial Biology Segment. “It's a powerful step forward in understanding the dynamic interplay within tissues that drives biology and disease.”
Traditional techniques for exploring molecular interactions typically assess proteins and RNA separately, which can result in the loss of spatial resolution. Meanwhile, bulk proximity assays fail to offer localization insights. Bio-Techne’s latest assay addresses both limitations by providing a highly visual, spatially resolved signal that can detect protein interactions directly within tissues.
The technology integrates seamlessly with the RNAscope™ Multiomic LS workflow on the BOND RX platform, enabling researchers to combine spatial protein detection with RNA analysis. This functionality is particularly important for applications that require spatial context — such as studies of immune checkpoint behavior, bispecific antibody targeting, and protein interactions within synapses.
Through its Early Access Program, Bio-Techne is offering select institutions and researchers the opportunity to incorporate this novel assay into their research pipelines. The company’s scientific team will present proof-of-concept data and early case studies during the 2025 American Association for Cancer Research (AACR) annual meeting.
About Bio-Techne Corporation
Bio-Techne (NASDAQ: TECH) is a global biotechnology firm offering a comprehensive range of tools and bioactive reagents that serve research and clinical diagnostic needs. The company supports critical investigations into cellular biology and disease pathways, aids in pharmaceutical development, and contributes to the advancement of clinical testing technologies. With a product portfolio numbering in the hundreds of thousands, Bio-Techne reported approximately $1.2 billion in net sales for fiscal year 2024. The company employs around 3,100 people across the globe. To learn more about Bio-Techne and its family of brands, visit www.bio-techne.com or follow the company on Facebook, LinkedIn, Twitter, and YouTube.